Antiphospholipid syndrome

In this autoimmune disorder, the immune system produces antibodies against phospholipid-associated proteins, primarily against beta-2-glycoprotein I and cardiolipin. As a result, the functioning of the coagulation system, endothelium, and platelets changes, making the blood more prone to thrombosis. This is important for individuals not only due to the risk of deep vein thrombosis or stroke. In women, antiphospholipid syndrome often manifests as recurrent pregnancy losses, fetal growth restriction, preeclampsia, and other placental complications. Therefore, this condition is considered not just a random laboratory finding but a full-fledged clinical problem that requires accurate diagnosis and monitoring.

What happens in the body

The key feature of the syndrome is that antibodies bind not only to the fats of cell membranes but also to carrier proteins that interact with phospholipids. Against this background, blood coagulation activity increases, the tendency for inflammation of the vascular wall grows, and the normal functioning of the inner lining of blood vessels is disrupted. As a result, thromboses can form in both the venous and arterial systems. Sometimes the process affects small vessels, and then the picture appears more blurred: headaches, livedo reticularis on the skin, episodes of ischemia, problems with placental blood flow, or persistent platelet abnormalities may occur.

Antiphospholipid syndrome can be primary, occurring on its own, or secondary, developing against the background of another autoimmune disease. It is most often discussed in conjunction with systemic lupus erythematosus, but a similar immune reconfiguration can occur in other clinical contexts as well. It is important not only to find antibodies but also to combine laboratory changes with real vascular or obstetric events. In some individuals, antibodies may be transiently detected after an infection or other immune stress, so a diagnosis cannot be made based on a single test.

What manifestations are considered typical

The clinical picture depends on where exactly blood flow is disrupted and how pronounced the thrombotic readiness is. The most typical scenarios to keep in mind are:

• deep vein thrombosis of the calf or thigh with pain, swelling, and a feeling of heaviness;
• pulmonary artery embolism with sudden shortness of breath, chest pain, and decreased exercise tolerance;
• ischemic stroke or transient ischemic attack, especially at a relatively young age;
• recurrent miscarriages, missed pregnancies, preeclampsia, or fetal growth restriction;
• livedo reticularis, episodes of skin cyanosis, ulcerative changes, or ischemia of the fingers;
• thrombocytopenia, migraine-like headaches, sometimes valvular heart changes, or renal vascular complications.

The most severe variant is called catastrophic antiphospholipid syndrome. It is rare but dangerous because multiple thromboses quickly affect several organs at once. This is already a situation for intensive care, not outpatient monitoring. That is why any signs of acute blood flow disturbance with suspected APS require urgent medical evaluation.

How the diagnosis is confirmed

For the diagnosis, not only a clinical episode is needed but also laboratory confirmation. The standard set usually includes lupus anticoagulant, antibodies to cardiolipin, and antibodies to beta-2-glycoprotein I. An important point is the need for repeated confirmation: tests must remain positive for at least 12 weeks; otherwise, elevated antibodies may be a temporary reaction after an infection or other immune event.

A complete blood count, platelet levels, coagulation indicators, kidney function, liver enzymes, and accompanying autoimmune markers are assessed separately if there are grounds to suspect a systemic disease. During pregnancy, doctors also monitor placental blood flow and fetal growth. If there have already been thromboses, it is important to analyze the entire risk picture: smoking, estrogen use, physical inactivity, obesity, surgeries, flights, dehydration, hypertension, and accompanying lipid or carbohydrate metabolism disorders.

A common mistake is to assume that any positive test for anticardiolipin antibodies automatically indicates antiphospholipid syndrome. This is not the case. A laboratory finding without clinical criteria does not equate to a disease, but it cannot be ignored if the person has already experienced thromboses, pregnancy losses, or persistent vascular complaints.

Pregnancy and reproductive risks

In obstetrics, this syndrome is particularly important because thromboses can occur not only in large vessels but also in small vessels of the placenta. This affects implantation, disrupts fetal nutrition, and increases the risk of early pregnancy loss. Preeclampsia, placental insufficiency, premature birth, and intrauterine growth restriction are also possible.

If a woman has already experienced recurrent miscarriages, missed pregnancies, or severe placental complications, the question of antiphospholipid antibodies usually arises quite early. With a confirmed diagnosis, the management plan for pregnancy is developed together with the doctor and often includes anticoagulant or antiplatelet support. It is not permissible to independently change this therapy, discontinue it, or replace it with supplements. Timing, dosage, and dynamic monitoring are particularly important here.

What is done in treatment and how lifestyle affects it

The basis of treatment depends on the clinical situation. If a person has already had a confirmed thrombosis, it most often involves long-term antithrombotic therapy. In pregnancy or when planning it, the approach is different, but the principle remains the same: the goal is not to “calm the antibodies” at any cost, but to reduce the risk of new vascular events and protect placental blood flow. In the secondary variant of APS, the underlying autoimmune disease is also monitored.

Lifestyle also matters, but as an addition, not as a replacement for therapy. Especially important are quitting smoking, controlling blood pressure, maintaining adequate physical activity, careful management of body weight, and preventing dehydration. For low-carbohydrate and ketogenic diets, there is a practical nuance: at the beginning of such a regimen, some people lose more fluid and electrolytes. If a person already has a thrombotic predisposition, significant dehydration, prolonged fasting without drinking, and uncontrolled use of diuretics or fat burners should be avoided. A keto diet alone does not treat antiphospholipid syndrome, but hydration quality, inflammatory load levels, glucose, and body weight can influence overall vascular risk.

In nutritional support, Omega-3, vitamin D, magnesium, and other anti-inflammatory factors are discussed, but they do not replace anticoagulant strategies where they are truly needed. Caution is especially required when combining supplements that affect platelet aggregation or coagulation with already prescribed medications. What appears to be gentle support in ordinary situations may increase the risk of bleeding in the context of anticoagulants.

When to seek help without delay

Urgent evaluation is needed in cases of sudden shortness of breath, chest pain, swelling of one leg, sudden weakness in the limbs, speech disturbances, sudden vision deterioration, severe new headaches, or rapid deterioration of well-being during pregnancy. This is not a situation where one should wait for the symptom to “pass on its own.” Antiphospholipid syndrome is primarily dangerous due to vascular complications, and the speed of response often determines the outcome.

If it is a planned review after tests or past episodes, the most useful step is to gather the complete picture: which specific antibodies were positive, whether there were repeated confirmations, whether real thromboses or obstetric complications occurred, what risk factors are present, and what the person is taking regularly. Only in this way can a random laboratory finding be separated from a condition that truly requires long-term monitoring and thoughtful prevention.